Show simple item record

dc.contributor.authorRodríguez Martínez, Alba
dc.contributor.authorMiguel-Pérez, Diego de
dc.contributor.authorOrtega, Francisco Gabriel
dc.contributor.authorGarcía Puche, José Luis 
dc.contributor.authorRobles Fernández, Inmaculada
dc.contributor.authorExpósito Hernández, José 
dc.contributor.authorMartorell Marugan, Jordi
dc.contributor.authorCarmona Sáez, Pedro
dc.contributor.authorGarrido Navas, María del Carmen
dc.contributor.authorRolfo, Christian
dc.contributor.authorIlyine, Hugh
dc.contributor.authorLorente Acosta, José Antonio 
dc.contributor.authorLegueren, Marta
dc.contributor.authorSerrano, María José
dc.date.accessioned2020-03-02T10:07:14Z
dc.date.available2020-03-02T10:07:14Z
dc.date.issued2019
dc.identifier.citationRodríguez-Martínez, A., de Miguel-Pérez, D., Ortega, F. G., García-Puche, J. L., Robles-Fernández, I., Exposito, J., ... & Ilyine, H. (2019). Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy. Breast Cancer Research, 21(1), 21.es_ES
dc.identifier.urihttp://hdl.handle.net/10481/59908
dc.description.abstractBackground: Breast cancer patients under neoadjuvant chemotherapy includes a heterogeneous group of patients who eventually develop distal disease, not detectable by current methods. We propose the use of exosomal miRNAs and circulating tumor cells as diagnostic and predictive biomarkers in these patients. Methods: Fifty-three breast cancer women initially diagnosed with localized breast cancer under neoadjuvant chemotherapy were prospectively enrolled in this study. However, six of them were later re-evaluated and diagnosed as metastatic breast cancer patients by PET-CT scan. Additionally, eight healthy donors were included. Circulating tumor cells and serum exosomal miRNAs were isolated from blood samples before and at the middle of neoadjuvant therapy and exosomal miRNA levels analyzed by qPCR. Results: Before neoadjuvant therapy, exosomal miRNA-21 and 105 expression levels were higher in metastatic versus non-metastatic patients and healthy donors. Likewise, higher levels of miRNA-222 were observed in basal-like (p = 0.037) and in luminal B versus luminal A (p = 0.0145) tumor subtypes. Exosomal miRNA-222 levels correlated with clinical and pathological variables such as progesterone receptor status (p = 0.017) and Ki67 (p = 0.05). During neoadjuvant treatment, exosomal miRNA-21 expression levels directly correlated with tumor size (p = 0.039) and inversely with Ki67 expression (p = 0.031). Finally, higher levels of exosomal miRNA-21, miRNA-222, and miRNA-155 were significantly associated with the presence of circulating tumor cells. Conclusion: Liquid biopsies based on exosomal miRNAs and circulating tumor cells can be a complementary clinical tool for improving breast cancer diagnosis and prognosis.es_ES
dc.description.sponsorshipThis work was supported by “Granada Research of Excellence Initiative on BioHealth (GREIB)”, the PhD grant from the University of Granada and the PhD grant from the Spanish Government (FPU) 2014, REF FPU14/05461es_ES
dc.language.isoenges_ES
dc.publisherSpringer Naturees_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectCirculating tumor cellses_ES
dc.subjectLocalized breast canceres_ES
dc.subjectNeoadjuvant chemotherapyes_ES
dc.subjectConservative surgeryes_ES
dc.subjectCancer diagnosises_ES
dc.subjectCancer prognosises_ES
dc.titleExosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.1186/s13058-019-1109-0


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución 3.0 España
Except where otherwise noted, this item's license is described as Atribución 3.0 España